HCA Healthcare (HCA) Q1 2026 earnings review
Top-Line Growth Stalls While Buybacks Mask Earnings Weakness
HCA Healthcare delivered a mixed first quarter. While management continues to execute its massive capital return program—driving a 10.9% increase in EPS—the underlying operations show clear signs of deceleration. Revenue grew 4.3% YoY, but Adjusted EBITDA barely moved at +1.9%, indicating margin compression. Volume metrics significantly missed the company's long-term 2-3% growth target, with equivalent admissions up just 1.3%, weighed down by a weak respiratory season and winter storms. However, unexpected state Medicaid supplemental payments provided a timely offset, allowing HCA to reaffirm its full-year 2026 guidance.
🐂 Bull Case
HCA retired 3.15 million shares ($1.57B) in Q1 alone, reducing outstanding shares by 9% year-over-year. Cash flow from operations surged 22% to $2.0B, easily funding aggressive buybacks and strategic CapEx.
Same facility revenue per equivalent admission increased 3.1% YoY to $18,692, demonstrating that HCA is still successfully managing rate increases despite volume softness.
🐻 Bear Case
Same facility equivalent admissions grew just 1.3%, well below the 2.4-2.8% range seen throughout 2025. Surgical volumes actually reversed into negative territory (-0.3% inpatient, -1.7% outpatient).
The expiration of enhanced premium tax credits (EPTCs) and potential tariff impacts threaten to strip $600M-$900M from EBITDA moving forward, placing immense pressure on cost-cutting initiatives to fill the gap.
⚖️ Verdict: ⚪
Neutral. The business is facing temporary macro headwinds (weather, mild flu season) and managing them adequately with Medicaid supplemental payments. But organic volume is undeniably decelerating, and long-term federal policy risks remain unresolved. The stock is currently being supported heavily by financial engineering (buybacks).
Key Themes
Buybacks Masking Flat Net Income
While reported diluted EPS grew an impressive 10.9% YoY to $7.15, this was almost entirely driven by a shrinking share count. Actual Net Income attributable to HCA grew a meager 0.6% ($1.620B vs $1.610B in 25Q1). If the company's aggressive buyback pace slows down, the lack of true bottom-line operating growth will become glaringly obvious to investors.
Sudden Deceleration in Surgical Volumes
Surgical volumes, a critical mix indicator for hospital profitability, reversed direction. Same facility inpatient surgeries fell 0.3% and outpatient surgeries dropped 1.7%. Management cited weak respiratory activity (-42% admissions) and January winter storms, but those macro factors primarily impact the ER, not scheduled surgeries. This warrants close monitoring next quarter to see if it is a structural loss of market share.
Medicaid Supplemental Programs Save the Quarter
Favorable recognition of certain state Medicaid supplemental programs directly offset the volume shortfall. Without these unguided policy tailwinds padding the top line, the 4.3% revenue growth and 1.9% Adjusted EBITDA growth would have likely been much weaker. HCA's ability to navigate state-level funding remains a critical, albeit volatile, margin driver.
Resiliency Program and AI Integration
To offset looming policy headwinds, HCA continues to aggressively push its 'Resiliency' initiative. The company is actively deploying AI and machine learning tools targeting administrative tasks (revenue cycle, HR), operational throughput, and clinical decision support. Management expects this structural shift in operations to generate hundreds of millions in structural savings, defending the margin profile against external shocks.
The Enhanced Premium Tax Credit (EPTC) Cliff
A severe macro overhang remains: the expected expiration of the EPTCs at the end of 2025. HCA models a 15-20% drop in its Health Insurance Exchange (HIX) volumes as a result, migrating previously insured, paying patients to uninsured status. This threatens to create a $600M-$900M gross EBITDA hole in late 2026 and 2027.
Robust Operating Cash Flow Generation
Despite margin compression, cash flows from operating activities accelerated, jumping 22.0% YoY to $2.014B. This liquidity gives HCA the firepower to continue expanding its ambulatory footprint, execute smaller M&A, and sustainably fund its massive $9.17B remaining share repurchase authorization.
Other KPIs
Decelerating. Equivalent admissions growth halved from 2.8% in 25Q1 and 2.5% in 25Q4 to just 1.3% in 26Q1, reflecting the impact of winter storms and a remarkably soft respiratory season. It sits well below the company's stated long-term run rate of 2-3%.
Accelerating slightly vs Q4 run rate. A 3.1% YoY increase signifies that, despite sluggish overall volumes, HCA continues to secure healthy pricing from commercial payers and benefit from acuity mix.
Reversing. Margin compressed 50 basis points from 20.4% in 25Q1. This highlights negative operating leverage: the fixed-cost nature of hospitals meant that the unexpected drop in patient volume hit profitability harder than the top line.
Guidance
Stable. Management reaffirmed prior guidance. The midpoint ($78.25B) implies roughly 4% YoY growth over FY25, demanding an acceleration in volumes for the remainder of the year to offset the Q1 shortfall.
Stable. The midpoint ($16.0B) represents moderate mid-single-digit YoY growth. Given the weak 1.9% growth in Q1, achieving this requires the Resiliency cost-cutting program to gain significant traction in Q2-Q4.
Stable. The midpoint of $30.30 reflects mid-single-digit growth versus FY25, heavily insulated by the expected continuation of aggressive share repurchases based on an assumed 223.5M ending share count.
Key Questions
Surgical Volume Softness
You attributed Q1 volume weakness largely to winter storms and low respiratory activity. However, outpatient surgeries declined 1.7%. Since these are typically scheduled cases unaffected by the ER funnel, are you seeing market share losses to ambulatory surgical centers (ASCs) or changing payer authorization behaviors?
Margin Target Feasibility
Adjusted EBITDA margin dipped below 20% this quarter despite the boost from Medicaid supplemental payments. As we lap tough YoY labor comparisons and face potential EPTC headwinds, what gives you confidence in maintaining a 20%+ margin profile through the back half of 2026?
Capital Deployment Priority
With Net Income growth largely stagnant this quarter, how much of your $5.0B-$5.5B CapEx budget is being allocated toward inorganic physician practice acquisitions vs. physical capacity expansion, in order to drive structural organic growth?